bioLytical Laboratories introduces affordable HIV self test in Kenya
Canada’s rapid infectious disease tests developer bioLytical Laboratories has unveiled its INSTI HIV Self Test for Kenya’s Pharmaceutical Association members.
Canada’s rapid infectious disease tests developer bioLytical Laboratories has unveiled its INSTI HIV Self Test for Kenya’s Pharmaceutical Association members.
The introduction of the self-test is a result of Clinton Health Access Initiative’s (CHAI) effort to offer low-cost HIV self-tests into pharmacies in Kenya.
The INSTI HIV Self Test is a blood-based self-test and is intended to be used as a screening tool to identify individuals who are suspected to be infected with HIV.
The assay detects HIV antibodies by examining a single drop of blood and provides instant results. INSTI is easy to use and provides almost accurate results.
The INSTI HIV Self Test is an over-the-counter (OTC) version of the bioLytical’s INSTI HIV-1 / HIV-2 Antibody Test, which is a rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick whole blood.
"The assay detects HIV antibodies by examining a single drop of blood and provides instant results."
bioLytical Laboratories chief technical officer Rick Galli said: ““Kenya is leading the way in bringing HIV self-testing into sub-Saharan Africa through the private sector.
“bioLytical is excited to lead in this ground-breaking initiative that will demonstrate how a low cost, accessible HIV self-testing programme can be effective and empowering for individuals to take control of their health”.
The introduction of the test will open access to affordable HIV testing for Kenyans across the country, through local pharmacies.
Image: HIV self-testing instructions. Photo: courtesy of bioLytical Laboratories.